



Applicants Copy

RECEIVED

FEB 27 2004

Customer Number 36441

Docket No. RTS-0353

PTO/SB/08A (08-00)

Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/024,369		
		Filing Date	December 17, 2001		
		First Named Inventor	Borchers, et al.		
		Group Art Unit	2812 1635		
Examiner Name	Gibbs				
Sheet	1	Of	1	Attorney Docket Number	RTS-0353

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)						
	AQ	WO	95/06718	A2	03-09-1995	Viagene, Inc.		
	AR	WO	95/06717	A2	03-09-1995	Viagene, Inc.		
Examiner Signature <i>[Signature]</i>					Date Considered	7/1/04		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DOCKET NO.: RTS-0353

"Express Mail" Label No.: EV053177129US
Date of Deposit: 12/17/2001

Form PTO-1449 Modified		Docket No. RTS-0353	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Alexander H. Borchers et al.	
		Filing Date herewith	Group 1635
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
pp	AA	Alimonti et al., TAP expression provides a general method for improving the recognition of malignant cells in vivo, Nat. Biotechnol., 2000, 18:515-520	
	AB	Bahram et al., Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region, Proc. Natl. Acad. Sci. U. S. A., 1991, 88:10094-10098	
	AC	Chen et al., A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer, Nat. Genet., 1996, 13:210-213	
	AD	Colonna et al., Allelic variants of the human putative peptide transporter involved in antigen processing, Proc. Natl. Acad. Sci. U. S. A., 1992, 89:3932-3936	
	AE	de la Salle et al., HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1, J. Clin. Invest., 1999, 103:R9-R13	
	AF	Furukawa et al., Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome, J. Clin. Invest., 1999, 103:755-758	
	AG	Galocha et al., The active site of ICP47, a herpes simplex virus-encoded inhibitor of the major histocompatibility complex (MHC)-encoded peptide transporter associated with antigen processing (TAP), maps to the NH2-terminal 35 residues, J. Exp. Med., 1997, 185:1565-1572	
	AH	Gorbulev et al., Allosteric crosstalk between peptide-binding, transport, and ATP hydrolysis of the ABC transporter TAP, Proc. Natl. Acad. Sci. U. S. A., 2001, 98:3732-3737	
	AI	Gromme et al., The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics, Eur. J. Immunol., 1997, 27:898-904	
pl	AJ	Jackson et al., TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined centromeric boundary of disease susceptibility, Proc. Natl. Acad. Sci. U. S. A., 1993, 90:11079-11083	
EXAMINER <i>Lee</i>		DATE CONSIDERED <i>7/1/04</i>	

3503 U.S. PTO
10/024369
12/17/01

DOCKET NO.: RTS-0353

Form PTO-1449 Modified		Docket No. RTS-0353	Serial No. not yet assigned 10/024,369
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Alexander H. Borchers et al.	
		Filing Date herewith	Group 1635
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SP	AK	Karttunen et al., Antigen presentation: TAP dances with ATP, Curr. Biol., 1999, 9:R820-824	
	AL	Klein et al., An inventory of the human ABC proteins, Biochim. Biophys. Acta, 1999, 1461:237-262	
	AM	Lage et al., Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone, FEBS Lett., 2001, 503:179-184	
	AN	Li et al., Tapasin is required for efficient peptide binding to transporter associated with antigen processing, J. Biol. Chem., 2000, 275:1581-1586	
	AO	Ljunggren et al., MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice, Int. Immunol., 1995, 7:975-984	
	AP	Min et al., Interferon induction of TAP1: the phosphatase SHP-1 regulates crossover between the IFN-alpha/beta and the IFN-gamma signal-transduction pathways, Circ. Res., 1998, 83:815-823	
	AQ	Reits et al., The major substrates for TAP in vivo are derived from newly synthesized proteins, Nature, 2000, 404:774-778	
	AR	Sospedra et al., Hyperexpression of transporter in antigen processing-1 (TAP-1) in thyroid glands affected by autoimmunity: a contributing factor to the breach of tolerance to thyroid antigens?, Clin. Exp. Immunol., 1997, 109:98-106	
	AS	Spies et al., A gene in the human major histocompatibility complex-class II-region controlling the class I antigen presentation pathway, Nature, 1990, 348:744-747	
PS	AT	Takeuchi et al., Association of TAP1 and TAP2 with systemic sclerosis in Japanese, Clin. Exp. Rheumatol., 1996, 14:513-521	
EXAMINER <i>[Signature]</i>		DATE CONSIDERED 7/1/04	

DOCKET NO.: RTS-0353

Form PTO-1449 Modified		Docket No. RTS-0353	Serial No. not yet assigned 10/024,369
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Alexander H. Borchers et al.	
		Filing Date herewith	Group 1635
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
PLB	AU	Takeuchi et al., Polymorphism of TAP1 and TAP2 in Japanese patients with rheumatoid arthritis, Tissue Antigens, 1997, 49:280-282	
f	AV	van Endert et al., Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes, Proc. Natl. Acad. Sci. U. S. A., 1992, 89:11594-11597	
	AW	Van Kaer et al., TAP1 mutant mice are deficient in antigen presentation; surface class I molecules, and CD4-8+ T cells, Cell, 1992, 71:1205-1214	
	AX	Vives-Pi et al., Expression of transporter associated with antigen processing-1 in the endocrine cells of human pancreatic islets: effect of cytokines and evidence of hyperexpression in IDDM, Diabetes, 1996, 45:779-788	
PLB	AY	Wong et al., Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides, J. Immunother., 1998, 21:32-40	
EXAMINER Lina J. R. L.		DATE CONSIDERED 7/1/04	

DOCKET NO.: RTS-0353

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. RTS-0353	Serial No. 10/094,369
U.S. Department of Commerce Patent and Trademark Office		Applicant Alexander H. Borchers et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date	Group 1635

U.S. PATENT DOCUMENTS						
Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA	6,087,122	7/11/2000	Hustad et al.	435	29
	AB	5,831,068	11/3/1998	Nair et al.	536	24.5
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS						
Examiner's Initial		Document No.	Date	Country	Translation YES NO	
	AO	WO 01/73027	10/4/2001	PCT	X	
	AP	WO 01/49716	7/12/2001	PCT	X	
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

EXAMINER	DATE CONSIDERED 7/1/04
----------	------------------------